Seasoned growth-stage investor and operating executive with experience across technology and healthcare investing, portfolio company operations, and capital raising. Chad Tobin brings a background blending corporate development, venture capital and hands-on operational leadership, often focusing on revenue scaling, go-to-market execution and M&A. Known for structuring growth equity investments and board-level oversight, works with founders and LPs to align strategic plans and exit pathways. Active in North American middle-market transactions.
Seasoned growth-stage investor and operating executive with experience across technology and healthcare investing, portfolio company operations, and capital raising. Chad Tobin brings a background blending corporate development, venture capital and hands-on operational leadership, often focusing on revenue scaling, go-to-market execution and M&A. Known for structuring growth equity investments and board-level oversight, works with founders and LPs to align strategic plans and exit pathways. Active in North American middle-market transactions.
Focuses on growth‑equity investments in North American middle‑market technology and healthcare companies, prioritizing revenue scaling, repeatable go‑to‑market models and strategic M&A to accelerate exits. Capital allocation favors lead or syndicate positions that provide board seats and operational influence; horizon is multi‑year, value‑creation driven. Underwrites companies by pairing revenue and unit economics momentum with disciplined downside protections. Investment edge derives from hands‑on operating experience, rigorous commercial KPIs and founder/LP alignment.
Focuses on growth‑equity investments in North American middle‑market technology and healthcare companies, prioritizing revenue scaling, repeatable go‑to‑market models and strategic M&A to accelerate exits. Capital allocation favors lead or syndicate positions that provide board seats and operational influence; horizon is multi‑year, value‑creation driven. Underwrites companies by pairing revenue and unit economics momentum with disciplined downside protections. Investment edge derives from hands‑on operating experience, rigorous commercial KPIs and founder/LP alignment.
| Trades 1341 | Longs Won 1003/1341 74% | Profit Factor 11.08 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $423,557.34 |
| Average Win $129,850.42 | Best Trade (Jul 15) $9.9M | Sharpe Ratio -13.49 |
| Average Loss -$34,762.76 | Worst Trade (Jul 10) -$805,013.04 | Z-Score 11.88 (100%) |
| Commissions $0 | Avg. Trade Length 1y 3w | Expectancy $88,359.55 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 9,804 | 8,824 | 7,843 | 6,863 | 5,882 | 4,902 | 3,922 | 2,941 | 1,961 | 980 |